Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib in Pulmonary Lymphangioleiomyomatosis
NCT02737202Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Apr 2016
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
A Phase 2 trial of saracatinib in Lymphangioleiomyomatosis (LAM), sponsored by Baylor College of Medicine. Started Apr 2016; status: terminated.
02
Drugs
saracatinib
03
Conditions
Lymphangioleiomyomatosis (LAM)
Beyond the preview
Go deeper on NCT02737202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737202.